siRNA directed against survivin enhances pancreatic cancer cell gemcitabine chemosensitivity

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Survivin overexpression is common in human cancers, including pancreatic cancer.
• Survivin contributes to resistance against radiation and chemotherapy treatments.
• Targeting survivin presents a potential therapeutic strategy for pancreatic cancer.

Purpose of the Study:

• To investigate the efficacy of survivin-targeted short interfering RNA (siRNA) in human pancreatic cancer cells.
• To evaluate the impact of survivin suppression on cancer cell growth, apoptosis, and cell cycle.
• To determine if survivin inhibition enhances chemosensitivity to gemcitabine.

Main Methods:

• Construction and transfection of a survivin siRNA plasmid expression vector into Panc-1 and BxPC3 cell lines.
• Detection of survivin mRNA and protein levels using RT-PCR and Western blot.
• Assessment of cell growth, cell cycle distribution, apoptosis, and cytotoxicity via trypan blue exclusion, flow cytometry, and MTT assay.

Main Results:

• Survivin siRNA treatment led to a significant reduction in survivin mRNA and protein expression.
• Suppression of survivin resulted in decreased tumor cell growth, increased spontaneous apoptosis, and G0/G1 cell cycle arrest.
• Survivin suppression markedly enhanced the chemosensitivity of pancreatic cancer cells to gemcitabine.

Conclusions:

• RNA interference (RNAi) targeting the survivin gene is a viable strategy for inhibiting pancreatic cancer progression.
• Survivin suppression can overcome chemoresistance, offering a potential approach for chemosensitization therapy.
• Targeting survivin holds promise as an adjuvant therapy to improve pancreatic cancer treatment outcomes.